Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Operating Leases (2022 - 2025)

Taysha Gene Therapies' Operating Leases history spans 4 years, with the latest figure at $16.5 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 7.01% year-over-year to $16.5 million; the TTM value through Sep 2025 reached $16.5 million, down 7.01%, while the annual FY2024 figure was $17.4 million, 8.4% down from the prior year.
  • Operating Leases for Q3 2025 was $16.5 million at Taysha Gene Therapies, down from $16.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $20.4 million in Q4 2022 and bottomed at $16.5 million in Q3 2025.
  • The 4-year median for Operating Leases is $18.3 million (2024), against an average of $18.3 million.
  • The largest annual shift saw Operating Leases fell 8.4% in 2024 before it fell 7.01% in 2025.
  • A 4-year view of Operating Leases shows it stood at $20.4 million in 2022, then decreased by 7.27% to $19.0 million in 2023, then fell by 8.4% to $17.4 million in 2024, then decreased by 4.92% to $16.5 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Operating Leases are $16.5 million (Q3 2025), $16.8 million (Q2 2025), and $17.1 million (Q1 2025).